Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

SalioGen Therapeutics

Pre-clinical

Pre-clinical

Therapeutic Approach

Restore CFTR Function

This program is studying a novel Gene Coding™ approach that is designed to turn on, turn off, or modify the function of any gene in the genome. In CF, this approach seeks to insert a large piece of healthy CFTR DNA at a precise location within the CFTR gene, which could enable the expression of a functional CFTR protein in essentially all individuals with CF, regardless of their individual mutation

Status

Laboratory studies to develop and test this technology are underway.

 

Sponsor

This program is sponsored by SalioGen Therapeutics and partially funded by the Cystic Fibrosis Foundation.



Contact us about SalioGen Therapeutics >